Efficacy and Safety of a Once-yearly Intravenous Zoledronic Acid 5 Mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older

Overview

Journal J Am Geriatr Soc

Specialty Geriatrics

Date 2010 Jan 15

PMID 20070415

Citations 48

Authors

Steven Boonen

Dennis M Black

Cathleen S Colon-Emeric

Richard Eastell

Jay S Magaziner

Erik Fink Eriksen

Peter Mesenbrink

Patrick Haentjens

Kenneth W Lyles

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine the efficacy of once-yearly intravenous zoledronic acid (ZOL) 5 mg in reducing risk of clinical vertebral, nonvertebral, and any clinical fractures in elderly osteoporotic postmenopausal women.

Design: A post hoc subgroup analysis of pooled data from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly (HORIZON) Pivotal Fracture Trial and the HORIZON Recurrent Fracture Trial.

Setting: Multicenter, randomized, double-blind, placebo-controlled trials.

Participants: Postmenopausal women (aged > or =75) with documented osteoporosis (T-score < or =-2.5 at femoral neck or >/=1 prevalent vertebral or hip fracture) or a recent hip fracture.

Intervention: Patients were randomized to receive an intravenous infusion of ZOL 5 mg (n=1,961) or placebo (n=1,926) at baseline and 12 and 24 months.

Measurements: Primary endpoints were incidence of clinical vertebral and nonvertebral and any clinical fracture after treatment.

Results: At 3 years, incidence of any clinical, clinical vertebral, and nonvertebral fracture were significantly lower in the ZOL group than in the placebo group (10.8% vs 16.6%, 1.1% vs 3.7%, and 9.9% vs 13.7%, respectively) (hazard ratio (HR)=0.65, 95% confidence interval (CI)=0.54-0.78, P<.001; HR=0.34, 95% CI=0.21-0.55, P<.001; and HR=0.73, 95% CI=0.60-0.90, P=.002, respectively). The incidence of hip fracture was lower with ZOL but did not reach statistical significance. The incidence rate of postdose adverse events were higher with ZOL, although the rate of serious adverse events and deaths was comparable between the two groups.

Conclusion: Once-yearly intravenous ZOL 5 mg was associated with a significant reduction in the risk of new clinical fractures (vertebral and nonvertebral) in elderly postmenopausal women with osteroporosis.

Citing Articles

Treatment of Osteoporosis and Osteoarthritis in the Oldest Old.

Fuggle N, Laslop A, Rizzoli R, Al-Daghri N, Alokail M, Balkowiec-Iskra E Drugs. 2025; 85(3):343-360.

PMID: 39969778 PMC: 11891106. DOI: 10.1007/s40265-024-02138-w.

Hormones and Aging: An Endocrine Society Scientific Statement.

Cappola A, Auchus R, Fuleihan G, Handelsman D, Kalyani R, McClung M J Clin Endocrinol Metab. 2023; 108(8):1835-1874.

PMID: 37326526 PMC: 11491666. DOI: 10.1210/clinem/dgad225.

Bone mineral density response to antiosteoporotic drugs in older depressed adults.

Efendioglu E, Cigiloglu A, Ozturk E, Ozturk Z Arch Osteoporos. 2023; 18(1):31.

PMID: 36781548 DOI: 10.1007/s11657-023-01219-9.

Fractures reduction with osteoporotic treatments in patients over 75-year-old: A systematic review and meta-analysis.

Guillaumin M, Poirson B, Gerazime A, Puyraveau M, Tannou T, Mauny F Front Aging. 2022; 3:845886.

PMID: 36404990 PMC: 9667050. DOI: 10.3389/fragi.2022.845886.

Treatment thresholds and minimal clinically important effect sizes of antiosteoporotic medication-Survey among physicians and lay persons in Germany.

der Keylen P, Zeschick N, Schlenz A, Kuhlein T PLoS One. 2022; 17(8):e0272985.

PMID: 35951613 PMC: 9371311. DOI: 10.1371/journal.pone.0272985.

References

Cauley J, Thompson D, Ensrud K, Scott J, Black D . Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11(7):556-61. DOI: 10.1007/s001980070075. View

Klotzbuecher C, Ross P, Landsman P, Abbott 3rd T, Berger M . Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15(4):721-39. DOI: 10.1359/jbmr.2000.15.4.721. View

McClung M, Geusens P, Miller P, Zippel H, Bensen W, Roux C . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344(5):333-40. DOI: 10.1056/NEJM200102013440503. View

Simonelli C, Killeen K, Mehle S, Swanson L . Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc. 2002; 77(4):334-8. DOI: 10.4065/77.4.334. View

van Eijken M, Tsang S, Wensing M, De Smet P, Grol R . Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature. Drugs Aging. 2003; 20(3):229-40. DOI: 10.2165/00002512-200320030-00006. View

Fox K, Magaziner J, Hawkes W, Yu-Yahiro J, Hebel J, Zimmerman S . Loss of bone density and lean body mass after hip fracture. Osteoporos Int. 2000; 11(1):31-5. DOI: 10.1007/s001980050003. View

Boonen S, McClung M, Eastell R, Fuleihan G, Barton I, Delmas P . Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc. 2004; 52(11):1832-9. DOI: 10.1111/j.1532-5415.2004.52506.x. View

Vestergaard P, Rejnmark L, Mosekilde L . Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int. 2007; 18(12):1583-93. DOI: 10.1007/s00198-007-0403-3. View

Colon-Emeric C, Kuchibhatla M, Pieper C, Hawkes W, Fredman L, Magaziner J . The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003; 14(11):879-83. DOI: 10.1007/s00198-003-1460-x. View

10.

Huybrechts K, Ishak K, Caro J . Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2005; 38(6):922-8. DOI: 10.1016/j.bone.2005.10.022. View

11.

Black D, Palermo L, Nevitt M, Genant H, Christensen L, Cummings S . Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1999; 14(1):90-101. DOI: 10.1359/jbmr.1999.14.1.90. View

12.

Chevalley T, Guilley E, Herrmann F, Hoffmeyer P, Rapin C, Rizzoli R . Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone. 2007; 40(5):1284-9. DOI: 10.1016/j.bone.2006.12.063. View

13.

Kado D, Browner W, Palermo L, Nevitt M, Genant H, Cummings S . Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1999; 159(11):1215-20. DOI: 10.1001/archinte.159.11.1215. View

14.

Gardner M, Brophy R, Demetrakopoulos D, Koob J, Hong R, Rana A . Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial. J Bone Joint Surg Am. 2005; 87(1):3-7. DOI: 10.2106/JBJS.D.02289. View

15.

Hannan E, Magaziner J, Wang J, Eastwood E, Silberzweig S, Gilbert M . Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA. 2001; 285(21):2736-42. DOI: 10.1001/jama.285.21.2736. View

16.

Andrade S, Majumdar S, Chan K, Buist D, Go A, Goodman M . Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003; 163(17):2052-7. DOI: 10.1001/archinte.163.17.2052. View

17.

Lu Y, Fuerst T, Hui S, Genant H . Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int. 2001; 12(6):438-44. DOI: 10.1007/s001980170087. View

18.

Gehlbach S, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood J . Recognition of vertebral fracture in a clinical setting. Osteoporos Int. 2000; 11(7):577-82. DOI: 10.1007/s001980070078. View

19.

Penning-van Beest F, Erkens J, Olson M, Herings R . Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin. 2008; 24(5):1337-44. DOI: 10.1185/030079908x297358. View

20.

Magaziner J, Lydick E, Hawkes W, Fox K, Zimmerman S, Epstein R . Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health. 1997; 87(10):1630-6. PMC: 1381125. DOI: 10.2105/ajph.87.10.1630. View